Viridian Synerbio Lactobacillus Rhamnosus GG 30 Veg Caps
Lactobacillus rhamnosus GG is the world's best documented strain of good bacteria. The special strain (GG) of bacteria is described in more than 750 scientific publications and has been subject to more than 250 clinical studies. Provides Lactobacillus rhamnosus GG at a clinically studied amount of 10 billion per capsule. Good gut bacteria species which are frequently found in food supplements include Lactobacillus and Bifidobacterium species.
What does Viridian Lactobacillus Rhamnosus Do?
LACTOBACILLUS RHAMNOSUS GG
Lactobacillus rhamnosus GG is a well-documented probiotic strain that has been identified in more than 760 scientific studies and 260 clinical trials. Probiotics are defined as living microorganisms that, when consumed at therapeutic levels, can confer a health benefit to the host. L rhamnosus GG originates from human intestinal microbiota and has been used worldwide since 1990 in food and dietary supplements. The probiotic has been linked to various health benefits including, reducing symptoms of irritated skin, food sensitivities, improving digestive health and child growth and development.
L rhamnosus GG has been labelled the ideal probiotic due to specific criteria (
A resistance to acid and bile
Ability to adhere to intestinal epithelial cells
Colonize human intestine
Produce antimicrobial substance against pathogenic bacteria
Good growth characteristics
L rhamnosus GG has the ability to transfer from a breast-feeding mother, in to her infant’s gut and colonize. A study investigated maternal probiotic supplementation postnatally while breast-feeding.
Results after 3 months found that only mothers supplementing with L rhamnosus GG bacteria, managed to colonize the infants gut.
FOOD ALLERGIES - Food allergies are becoming an increasing public health concern, with cow’s milk allergies presenting the most common in early childhood. Growing evidence suggests that alterations in gut microflora composition by environmental factors such as diet or antibiotics, may play a central role in the development of food allergies. L rhamnosus GG is thought to offer treatment and prevention against food allergies, by regulating components involved in an immune response. Another possible mechanism could be through the reduction in permeability of the mucosal barrier, therefore inhibiting antigens crossing and leading to sensitization of the immune system. A study incorporated L rhamnosus GG at 25 million to hydrolyzed casein formula for infants with an allergy to cow’s milk. Results saw an improvement in the recovery of inflamed colonic mucosa in the treatment group of infants, and inflammatory markers in fecal matter were reduced.
ACNE - Probiotics are increasingly being explored as a potential treatment strategy for skin disorders with new evidence to suggest the strain L rhamnosus GG may also be beneficial in cases of acne. Both the gut-skin axis and dysregulation of insulin signaling have been implicated in the pathogenesis of adult acne, therefore research has investigated the effect of L rhamnosus GG in skin expression of genes involved in insulin signaling and hence improvement in acne. The outcome of a randomised, double-blinded, placebo-controlled study found that supplementation with the strain L rhamnosus GG at a dose of 3 billion for 12 weeks normalises skin expression of genes involved in insulin signaling and improves the appearance of adult acne.
ECZEMA - A large proportion of Infant atopic eczema/dermatitis is associated with an allergic reaction to a food hypersensitivity. Clinical trials have found positive results from administering L rhamnosus GG to mothers, with previous or current atopic disease, during and after pregnancy. Supplementing with L rhamnosus GG alongside lactation, could improve the immuno-suppressive potential of the mother’s breast milk . Kallimomaki, randomized 159 prenatal women with at least one first-degree relative or partner with atopic eczema.
The treatment group were given L rhamnosus GG (1 Å~ 1010 colony-forming units) before, and after pregnancy until the infant was 6 months old. L rhamnosus GG was effective at preventing atopic allergies in infants, the frequency of atopic eczema in the probiotic group was half that of the placebo group.
An additional study investigated the effect of treating mothers with L rhamnosus GG 10 billion daily from 2-4 weeks prenatally, until 24 weeks postnatally. The incidence of eczema in infants up until the age of 7 was documented. Risk of developing eczema during the first 7 years of life was significantly lower in the L rhamnosus GG group than in the placebo, and after 2 years’ eczema frequency was halved in the L rhamnosus GG compared to placebo
L rhamnosus GG reduces incidence of dermatitis in infants of mothers who supplemented with the probiotic over a 7-year period.
DIGESTIVE HEALTH -the interaction between our gut flora and a normal immune response is very important. Dysregulation of this response can lead to an inflammatory response of the gut, thus multiple disease can arise including, Irritable Bowel syndrome (IBS), and in more serious cases inflammatory bowel diseases (IBD) such as ulcerative colitis or chrohn’s disease.
A trial investigated the effects of children with IBS, supplementing daily with oral L rhamnosus GG at 3 billion for 8 weeks. Children in the treatment group had significantly reduced symptoms of abdominal pain, and a decrease in the number showing abnormal results for intestinal permeability. Results were sustained after the 8 week follow up.
L rhamnosus GG reduces mean weekly number of pain episodes and severity suffered by children.
Supplementing with L rhamnosus GG10(10) twice daily for 6 months, was beneficial for children suffering with Crohn’s disease. After one week of treatment a significant improvement was seen, and this was sustained throughout the study period. Intestinal permeability also improved over time.
DIARRHOEA - A lot of evidence supports a beneficial effect of L rhamnosus GG treatment for acute diarrhea in children. A large European study investigated 287 children, aged 1-36 months in 10 countries, with moderate to severe diarrhea. Children were given L rhamnosus GG 10 billion daily alongside a standard oral rehydration solution or placebo. Patients given L rhamnosus GG G had a shorter duration and decreased severity of illness, and were less likely to have persistent diarrhea compared to placebo.
A study investigated 81 children aged 1-36 months who had been hospitalized, and were administered L rhamnosus GG at (6 billion twice daily). Results found an 80% reduced risk of contracting Nosocomial diarrhea, commonly caused by an enteric viral pathogen, in comparison with placebo. incidence of diarrhoea is reduced in children treated with L rhamnosus GG
The prevalence of cases of diarrhoea associated with antibiotic therapy is slowly rising in the pediatric population. It is assumed that antibiotic associated diarrhoea (AAD) is a result of the disruption of the gut microflora balance. L rhamnosus GG has shown efficacy for the prevention of AAD. A Systematic review of the data from 12 control trials found L rhamnosus GG as a significantly effective treatment for the prevention of AAD for children and adults, risk was reduced from 22.4% to 12.3%12.
Travelers to undeveloped countries are subject to a high incidence of diarrhoea, ranging from 25-50%. A large Finnish study randomized 756 subjects travelling to two resorts in Turkey, they were given L rhamnosus GG (10(10)), or placebo. L rhamnosus GG group were significantly protected from travelers’ diarrhea by 39.5% in the first week, and 27.95% in the second week compared with placebo.
INTESTINAL PERMEABILITY- L rhamnosus GG has several beneficial mechanisms involved in supporting and improving gut health. One common pathology associated with IBS, is an increase in intestinal permeability. The cells lining the gut are the first line of defense against external components, disruption of the tight junctions between these cells leads to a leaky gut causing an inflammatory response. Evidence suggests L rhamnosus GG could have a direct effect on tight junction integrity in the gut.
A study investigated children with irritable bowel syndrome or functional pain. They received L rhamnosus GG 10 or placebo for 8 weeks with an additional 8-week follow-up. The treatment group had a significant reduction in the frequency and severity of abdominal pain, which carried on till the end of the follow up. The treatment group also had a significant reduction in the number of patients with intestinal permeability, compared with placebo.
Supplementing with L rhamnosus GG (1010) for 4 weeks, after children had suffered with rotavirus and cryptosporial diarrhea, significantly improved gut health. Fewer children in the treatment group had impaired intestinal function (48% vs 72%), number of subsequent diarrheal episodes (25% vs. 46%) and there was an increased IgG response.
RESISTANCE TO INFECTION - Children attending day care centers are 1.5-3 times more likely to contract a GI or respiratory tract infection, than children at home.
Supplementing with L rhamnosus GG helps support and strengthen the immune system. It improves gut health by balancing the microflora, and influences the immune response by specifically stimulating antibody production and enhancing phagocytic activity. A randomized control trial investigated long term administration of milk containing L rhamnosus GG on the frequency of gastrointestinal and respiratory infections in children aged 1-6 years.
Results found children in the probiotic group had fewer days off day-care due to illness, there was a 17% reduction in children suffering with respiratory tract infections.
L rhamnosus GG reduces infections and antibiotic use.
CHILD DEVELOPMENT - By providing a good human-microflora relationship, we can efficiently digest and absorb energy from nutrients. Intestinal microflora is essential for providing the correct enzymes and biochemical pathways required for humans to obtain the nutrients they need, especially during growth and development.
Emerging scientific data suggests that the presence of a healthy gut microflora, especially certain beneficial bacteria/probiotics, could positively alter the development of the nervous system. A study investigated the effects of children supplementing with L rhamnosus GG during the first 6 months of their lives, in preventing the manifestation of attention deficit hyperactivity disorder (ADHD) and Asperger Syndrome (AS). A follow up was carried out when the children reached 13 years old. 17% were diagnosed with either ADHD or AS in the placebo, whereas there were no cases in the L rhamnosus GG group.
Some evidence suggests a beneficial role of L rhamnosus GG in rheumatoid arthritis (RA), by regulating mediators of an inflammatory response inflicted at joints. Patients with RA were given to capsules of L rhamnosus GG (5(109)) or placebo, twice daily for 12 months. Results found a beneficial trend for the treatment group, there was an overall mean reduction of tender and swollen joints. RA activity was reduced by 71% (treatment group) vs. 30%
Synbiotic Mother & Baby
Each scoop provides:
Lactobacillus ramous GG 10 billion
* Full spectrum prebiotic fructooligosaccharide and plant-derived inulin
Dose: Pregnant and breastfeeding mothers: 1 to 2 scoops per day. Infants (from birth to 3 years): one
scoop per day.
Synbiotic Lactobacillis ramous GG
Each capsule provides:
Lactobacillus ramous GG 10 billion
* Full spectrum prebiotic fructooligosaccharide and plant-derived inulin
Dose: Adults: 1 capsule per day.
Safety: Tolerated well, no documented side effects. Safe during pregnancy and breast-feeding19.
Contraindications: Professional supervision is recommended in people taking immunosuppressant
medications or who are immunocompromised e.g. infants, elderly or critical illness.
Directions: As a food supplement, take one to two capsules twice daily with food, or as recommended by your healthcare professional.
One capsule provides:
|Lactobacillus rhamnosus GG||10 billion|
|*full spectrum prebiotic fructooligosaccharide and plant derived inulin|